How is continuous glucose monitoring (CGM) transforming pregnancy care? In this special episode, maternal-fetal medicine expert Dr. Stacey Ehrenberg and diabetes educator Joy Cornthwaite, RD, join Real-Time Real Talk to break down the latest research from the ADA Conference and share real-world stories of Dexcom G7 in action. Discover how CGM empowers patients and providers, overcomes clinical barriers, and delivers personalized insights for healthier pregnancies and beyond.

Listen now: https://provider.dexcom.com/education-research/podcast

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. 

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.

Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.

“Dexcom" refers to the Dexcom CGM.

Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7.

The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.

G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Brief Safety Statement:       

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

STELO IMPORTANT INFORMATION: Consult your healthcare

Only 1 in 5 people with type 2 diabetes on insulin use Continuous Glucose Monitoring (CGM) and for those not on insulin, that number drops to just 5%. With real-time glucose tracking transforming how patients understand and manage their health, why isn’t CGM more widely used? In this live episode from the American Diabetes Association (ADA) Conference, Real-Time Real Talk explores the barriers, breakthroughs, and future of diabetes technology. You'll hear why CGM is gaining traction not just for type 1 diabetes, but also in primary care, prediabetes, and even among the glucose-curious.

--

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.

Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.

“Dexcom" refers to the Dexcom CGM.

Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7.

The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.

G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Brief Safety Statement:                                                                                                       

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.


MAT-9989

Lance Bass discusses an honest look at misdiagnosis, diabetes stigma, and how real-time Continuous Glucose Monitoring (CGM) transformed his life on this special episode of Real-Time Real Talk recorded live at the American Diabetes Association conference (ADA) in Chicago this June.

When Lance was first diagnosed with type 2 diabetes, it didn’t make sense - he ate well, exercised, and didn’t fit the typical profile. But as his glucose remained high and symptoms worsened, he discovered he actually had LADA (Latent Autoimmune Diabetes in Adults), a slow-progressing form of type 1 diabetes.

Host Cher Pastore, MS, RD, CDCES, BC-ADM sits down with Lance to unpack his journey from misdiagnosis to managing his condition with CGM and advanced diabetes technology.

Lance shares how CGM with the Dexcom G7 transformed his diabetes management, allowing him to see blood sugar levels in real time, avoid dangerous lows, and personalize his food and insulin decisions. They discuss everything from automated insulin delivery systems to blood sugar monitoring tips, glucose sensors, and the mental relief that comes from not having to guess what’s happening in your body.

He also opens up about raising awareness, reducing stigma for young people with diabetes, and why showing his G7 publicly has helped others feel seen and supported.

Whether you're a healthcare provider, parent, or person living with diabetes, this episode offers powerful insight into the life-changing potential of CGM technology and is a must-listen for anyone affected by type 1 diabetes, type 2 diabetes, or prediabetes - including patients, endocrinologists, and primary care providers. The interview offers an honest and insightful look at how biosensor tools like CGM are reshaping diabetes treatment, diabetes education, and metabolic health outcomes.

Even for those not on insulin, Continuous Glucose Monitoring (CGM) is transforming the way HCPs approach diabetes treatment. Cher Pastore, MS, RD, CDCES, BC-ADM and guest David Doriguzzi, a Physician Assistant in endocrinology and internal medicine explore how Dexcom G7 and Stelo are reshaping diabetes management for people with type 1 diabetes, type 2 diabetes, and prediabetes.

Together, they break down how Dexcom’s portfolio provides real-time glucose monitoring, reveals patterns invisible through traditional blood sugar monitoring, and inspire meaningful behavior change.

David shares patient stories that demonstrate how CGM is helping individuals recognize how food, activity and medications impact their diabetes management. He also explains how CGM empowers providers to tailor diabetes education and medication strategies, especially in primary care settings with limited access to endocrinologists. 

Whether you’re managing type 1 diabetes, type 2 diabetes or on the journey to prevent it, this conversation showcases how diabetes technology like CGM can simplify treatment decisions, personalize care, and ultimately make an impact for both patients and providers.

Pregnant Patients are Empowered by Real-Time Continuous Glucose Monitoring (CGM): How Biosensor Technology Supports Type 1 Diabetes, Type 2 Diabetes, Prediabetes, and Gestational Diabetes

How does real-time data from Continuous Glucose Monitoring (CGM) reshape how we talk about food, exercise, and metabolic health Exploring how CGM - and tools like Dexcom and Stelo are empowering people with type 1 diabetes, type 2 diabetes, and even prediabetes to better understand their glucose patterns and take charge of their diabetes management is host Cher Pastore, MS, RD, CDCES, BC-ADM, joined by Rachel Stahl Salzman, a registered dietitian and certified diabetes education specialist at Weill Cornell. 

Rachel shares practical insights from her work in diabetes treatment, including with pregnant patients managing gestational diabetes. She also discusses her recent study presented at Advanced Technologies & Treatments for Diabetes (ATTD), where CGM use helped women with gestational diabetes feel more confident and in control of their care. 

From glucose tracking to blood sugar monitoring, this episode explores how biosensor technology supports more personalized, effective diabetes management - not just for patients, but for endocrinologists and primary care providers too.

Whether you’re focused on diabetes treatment, nutrition, or simply curious about the future of diabetes technology, this episode of Real-Time Real Talk reveals how CGM is making care more precise, proactive, and powerful.

Brought to you by Dexcom https://provider.dexcom.com/education-research/podcast

How can Continuous Glucose Monitoring (CGM) help people with type 2 diabetes feel more empowered and in control of their health? Exploring compelling new research presented at the Advanced Technologies & Treatments for Diabetes (ATTD) conference is host Cher Pastore, MS, RD, CDCES, BC-ADM, and guest Sim Singh, Senior Director of Behavioral and Translational Science at Dexcom.

Together, they unpack findings from a 30-day study of Dexcom G7 use in people with type 2 diabetes, including those not on insulin. The results show significant improvements in glucose tracking, behavioral shifts like better nutrition and increased physical activity, and enhanced metabolic health and confidence - especially among CGM-naive users. Sim also shares insights from a Canadian trial and discusses how CGM is transforming diabetes education, not only for patients but for endocrinologists and primary care providers as well.

Whether it’s supporting blood sugar monitoring, enabling personalized diabetes treatment, or simply helping people better understand their glucose patterns, this conversation highlights how CGM and biosensor technology are reshaping diabetes management - for people with type 1 diabetes, type 2 diabetes, and even prediabetes.

Integrating glucose sensor Dexcom G7 with digital health apps like Happy Bob and Undermyfork is improving diabetes treatment decisions and patient engagement. Whether it’s gamifying glucose tracking, uncovering personalized glucose patterns, or making real-time adjustments, these digital tools empower both patients and providers.

Cher Pastore, MS, RD, CDCES, BC-ADM is joined by diabetes experts Jami Klein, BSN, RN, CDCES and Rachael Sood, RN, MSN, APRN, NP-C, CDCE to explore how apps like Happy Bob and Undermyfork integrate with Continuous Glucose Monitoring (CGM) to make tracking blood sugar levels more interactive and insightful.

Rachael shares real-world experiences from her diabetes care clinic, demonstrating how CGM-driven insights help patients with Type 1 diabetes, Type 2 diabetes, and prediabetes make better-informed treatment decisions. Jami brings her personal perspective on using CGM and apps to optimize diabetes management, highlighting the role of glucose sensors, blood sugar monitoring, and biosensor technology in simplifying daily care.

Together, they explore how diabetes technology is reshaping diabetes education, treatment, and metabolic health, and how digital health solutions are making a lasting impact in endocrinology and primary care.

Brought to you by Dexcom https://www.dexcom.com/

Welcome back to another episode of Real-Time Real Talk where this week, host Cher Pastore is joined by Dr Thomas Grace and Dr. William Polonsky to discuss the power of Continuous Glucose Monitoring (CGM) in managing type 2 diabetes.

Continuous Glucose Monitoring has revolutionized the management of diabetes. At its core, diabetes management is about balancing blood glucose levels to avoid the serious complications associated with hyperglycaemia and hypoglycaemia. CGM technology provides both patients and healthcare professionals with real-time data on glucose levels, making it a powerful tool in this balancing act.

In this episode Dr Grace and Dr Polonsky share their insights from their research, highlighting significant reductions in A1C levels and improvements in patient outcomes with the use of CGM. They highlight the clinical benefits of CGM for managing glucose levels and making informed dietary and lifestyle choices. Additionally, they discuss the psychological effects of CGM including increased engagement, empowerment, and reduced anxiety. 

Dr Grace also introduces an exciting new product from Dexcom called Stelo, which will be an over the counter option for patients with type two diabetes (not on insulin), meaning that if your doctor is unwilling to write you a prescription for a Dexcom G7, you yourself can go to www.stelo.com and see if an over the counter product is appropriate for you. 

Welcome back to another episode of Real-Time Real Talk. This week, host Cher Pastore is joined by Emily Cornelius, a Registered Dietitian, to discuss the science behind monitoring glucose levels in individuals with prediabetes and type 2 diabetes who are not on insulin as well as introducing a brand new product by Dexcom called Stelo. 

Having faced challenges with dieting as a young adult, Emily discovered the importance of nutrition. This experience set her on a career path and a personal mission to help more women love the way they look, eat, and feel. Through her work, she focuses on helping exhausted dieters achieve their goals by addressing the root cause of weight gain (insulin resistance) while still enjoying the foods they love. She is also well-known across social media platforms, where she highlights creative ways to eat healthily without letting diet consume all their time.

In this episode, Emily shares her experience using continuous glucose monitoring (CGM) and how it has helped her clients with insulin resistance and weight loss. They discuss the impact of glucose sensors on behavior change, the importance of personalized nutrition plans, and the accessibility of glucose sensors without a prescription. They also highlight the benefits of using glucose sensors in managing prediabetes and making informed food and exercise choices.

Emily and Cher also look at the brand-new product from Dexcom, Stelo, a glucose biosensor indicated for people with type 2 diabetes or prediabetes. Stelo tracks glucose 24/7, revealing how food, exercise, and even sleep can affect glucose levels, helping you become a healthier you.

Visit www.stelo.com to find out more.